Internet-based transdiagnostic treatment for emotional disorders in Arabic- and Farsi-speaking refugees: a randomized controlled trial.

Not Applicable

Recruiting

• Conditions: F40.0; F40.1; F43; F10; F19; F63; Depressive episode; Unspecified mood [affective] disorder; F32; F39

• Registration Number: DRKS00024154
• Lead Sponsor: Medical School Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-02-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 131

Inclusion Criteria

Legal age
- Primary diagnosis of a depressive disorder, a post-traumatic stress disorder (PTSD) or an anxiety disorder (generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder) according to DSM-5
- Arabic language skills (spoken and written)
- Access to the Internet (smart phone or computer)
- Approval of the declaration of consent

Exclusion Criteria

- Current psychotic or bipolar disorder
- Severe substance use disorder (AUDIT Score> 15 for men,> 13 for women; DUDIT Score> 25)
-Acute suicidality (lack of or unclear distancing; no ability to agree/respond)
- Suicide attempt in the past 12 months
- Ongoing psychotherapy or unstable medication with psychotropic drugs three months before the start of the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is the change in psychological distress as assessed using the total score of the HSCL-25 self-report version (from pre- to post-assessment).

Secondary Outcome Measures

Name	Time	Method
As secondary results depression is assessed using the subscale HSCL-25 depression, anxiety using the subscale HSCL-25 anxiety and post-traumatic symptoms using the PCL-5. A suicide screening will be conducted during the diagnostic phone interview. The AUDIT will be used to assess alcohol consumption, the DUDIT to assess drug consumption, and the EQ-5D-5L to record the quality of life and, at the same time, the somatic symptom burden. <br>Satisfaction with treatment will be assessed with the CSQ-I. Potential side effects will be measured with the NEQ.